Format

Send to

Choose Destination
Oncotarget. 2016 Nov 8;7(45):73080-73100. doi: 10.18632/oncotarget.11485.

Dandelion root extract affects colorectal cancer proliferation and survival through the activation of multiple death signalling pathways.

Author information

1
Department of Chemistry & Biochemistry, University of Windsor, Windsor ON, Canada.
2
Department of Biology, University of Ottawa, Ottawa ON, Canada.
3
Red de Estudios Moleculares Avanzados, Instituto de Ecología A.C. Xalapa, Veracruz, México.

Abstract

Dandelion extracts have been studied extensively in recent years for its anti-depressant and anti-inflammatory activity. Recent work from our lab, with in-vitro systems, shows the anti-cancer potential of an aqueous dandelion root extract (DRE) in several cancer cell models, with no toxicity to non-cancer cells. In this study, we examined the cancer cell-killing effectiveness of an aqueous DRE in colon cancer cell models. Aqueous DRE induced programmed cell death (PCD) selectively in > 95% of colon cancer cells, irrespective of their p53 status, by 48 hours of treatment. The anti-cancer efficacy of this extract was confirmed in in-vivo studies, as the oral administration of DRE retarded the growth of human colon xenograft models by more than 90%. We found the activation of multiple death pathways in cancer cells by DRE treatment, as revealed by gene expression analyses showing the expression of genes implicated in programmed cell death. Phytochemical analyses of the extract showed complex multi-component composition of the DRE, including some known bioactive phytochemicals such as α-amyrin, β-amyrin, lupeol and taraxasterol. This suggested that this natural extract could engage and effectively target multiple vulnerabilities of cancer cells. Therefore, DRE could be a non-toxic and effective anti-cancer alternative, instrumental for reducing the occurrence of cancer cells drug-resistance.

KEYWORDS:

cancer; gene expression; natural health product; oxidative stress; phytochemical composition

PMID:
27564258
PMCID:
PMC5341965
DOI:
10.18632/oncotarget.11485
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center